MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • MDS Virtual Congress 2021

    Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS

    P. Dole, S. Green, M. Wiggins, J. Joseph, M. Gaspari, M. Siddiqui (Winston-Salem, USA)

    Objective: To examine the efficacy and safety of LCIG in a ‘real world’ tertiary care center setting in patients with and without DBS. Background: Levodopa-Carbidopa…
  • MDS Virtual Congress 2021

    Adherence to medication among Serbian Parkinson’s disease patients: a cross-sectional study

    A. Milovanović, B. Radojević, NT. Dragašević-Mišković, M. Svetel, I. Petrović, A. Tomić-Pešić, M. Savić, D. Stanisavljević, VS. Kostić (Belgrade, Serbia)

    Objective: This study aimed to explore patients’ adherence to antiparkinsonian medication, and to determine factors associated with low adherence among Serbian PD patients. Background: Adherence…
  • MDS Virtual Congress 2021

    Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease

    FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio (Burjassot, Spain)

    Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease…
  • MDS Virtual Congress 2021

    Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease

    JB. Zhang, C. Ren, KJ. He, F. Wang, CF. Liu (Suzhou, China)

    Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…
  • MDS Virtual Congress 2021

    Time to diagnosis of clinically established Parkinson’s disease or atypical parkinsonism: is a 5-year follow-up period necessary?

    M. Rossi, S. Perez-Lloret, M. Merello (Buenos Aires, Argentina)

    Objective: To determine the time frame to the diagnosis of clinically established Parkinson’s disease (PD) or atypical parkinsonism after an acute levodopa challenge (LDC) for…
  • MDS Virtual Congress 2021

    Rapidly progressive dementia after MRI-guided Focused Ultrasound (MR-FUS)

    JM. Perez Imbernon, S. Lopez Calvo, F. Castillo Alvarez, MT. Marti Sanchez, MM. Zambrano Vera, N. Reurich Gomez, ME. Marzo Sola (Logroño, Spain)

    Objective: To present a Parkinson´s Disease (PD) patient who presented a rapidly progressive dementia after MR-FUS therapy. Background: MR-FUS thalamotomy is used for unilateral essential…
  • MDS Virtual Congress 2021

    Mild cognitive impairment does not predict development of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson’s disease

    SF. Fjeldhøj, BLC. Thomsen, PMP. Pedersen, SRJ. Jensen, MK. Karlsborg, AL. Løkkegaard (Copenhagen, Denmark)

    Objective: This is a long-term follow-up study of a group of patients with levo-dopa responsive fluctuating Parkinson’s disease (PD), with focus on the short- and…
  • MDS Virtual Congress 2021

    Prognostic Modeling of Parkinson’s Disease Progression Using Early Longitudinal Patterns of Change

    X. Ren, J. Lin, G. Stebbins, C. Goetz, S. Luo (Foster City, CA, USA)

    Objective: To develop a prognostic model using multiple longitudinal measures to predict temporal clinical progression in early PD. Background: Predicting time to Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    The Commercial Genetic Testing Landscape for Parkinson’s Disease

    L. Cook, J. Schulze, J. Verbrugge, C. Klein, A. Naito, R. Alcalay (Indianapolis, USA)

    Objective: To evaluate commercial genetic testing offered for Parkinson’s disease (PD) Background: The etiology of PD is complex and, typically, multifactorial. At least 6 genes…
  • MDS Virtual Congress 2021

    Increased stroke risk in Parkinson’s disease patients with LRRK2 mutations

    D. Macias-Garcia, MT. Periñán, L. Muñoz-Delgado, S. Jesús, MV. Jimenez-Jaraba, D. Buiza-Rueda, M. Bonilla-Toribio, A. Adarmes-Gomez, F. Carrillo, P. Gómez-Garré, P. Mir (Seville, Spain)

    Objective: To determine whether genetic forms of Parkinson’s Disease (PD), such as LRRK2-mutated PD (LRRK2-PD) and GBA­-mutated PD (GBA­-PD), have a different vascular risk compared…
  • « Previous Page
  • 1
  • …
  • 381
  • 382
  • 383
  • 384
  • 385
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley